Quantitative Predictive Modelling Approaches to Understanding Rheumatoid Arthritis:A Brief Review [PDF]
, 2019 Rheumatoid arthritis is a chronic autoimmune disease that is a major public health challenge. The disease is characterised by inflammation of synovial joints and cartilage erosion, which lead to chronic pain, poor life quality and, in some cases ...
Chaplain, Mark A. J. +2 more
core +4 more sources
The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients [PDF]
, 2022 OBJECTIVES: This study was to determine whether the BILAG2004-Pregnancy Index (BILAG2004-P) has construct/criterion validity and is sensitive to change. METHODS: This was an observational multicentre study that recruited pregnant SLE patients.
Akil, Mohammed +7 more
core +1 more source
Effect of filgotinib on health-related quality of life in active psoriatic arthritis:a randomized phase 2 trial (EQUATOR) [PDF]
, 2020 To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life (HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in active PsA.
Besuyen, Robin +11 more
core +1 more source
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3 [PDF]
, 2021 OBJECTIVE: This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with multiple poor prognostic factors (PPFs).
Adami, Giovanni +12 more
core +6 more sources
Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland:data from the COVID-19 Global Rheumatology Alliance registry [PDF]
, 2022 OBJECTIVES: Although evidence is accumulating globally, data on outcomes in rheumatic disease and COVID-19 in Ireland are limited. We used data from the COVID-19 Global Rheumatology Alliance (C19-GRA) to describe time-varying COVID-19 outcomes for people
,
core +1 more source
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study [PDF]
, 2017 Background Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. Methods In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and ...
Aletaha +43 more
core +2 more sources
Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status [PDF]
, 2022 OBJECTIVE: To describe obstetric outcomes based on COVID-19 vaccination status, in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.
Aguiar, Mathia Cecilia +64 more
core
Filgotinib for the treatment of rheumatoid arthritis [PDF]
Expert Opinion on Investigational Drugs, 2017 Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy. Being proteins, they are administered parenterally. The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA ...
Taylor, P, Abdul Azeez, M, Kiriakidis, S
openaire +2 more sources
Drugs in ContextBackground Filgotinib, an oral Janus kinase 1 preferential inhibitor, has been shown to be an effective treatment for ulcerative colitis (UC) in pre-registration studies.
David Young +21 more
semanticscholar +1 more source
RMD OpenObjectives Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse ...
X. Mariette +19 more
semanticscholar +1 more source